Terlipressin
- Generic Name
- Terlipressin
- Brand Names
- Terlivaz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 14636-12-5
- Unique Ingredient Identifier
- 7Z5X49W53P
- Background
Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in vari...
- Indication
Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.
- Associated Conditions
- Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension
- Associated Therapies
- -
Terlipressin Administration in Septic Shock Refractory to Catecholamines
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2008-11-19
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00793559
- Locations
- 🇮🇱
Asaf Harofeh MC, Zrifin, Israel
Terlipressin in Septic Shock in Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 72
- Registration Number
- NCT00628160
- Locations
- 🇪🇸
Hospital Clinic Barcelona, Barcelona, Catalonia, Spain
The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
- Conditions
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2007-12-05
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 320
- Registration Number
- NCT00534677
- Locations
- 🇵🇰
The Aga Khan University Hospital, Karachi, Sindh, Pakistan
Continuous Infusion of Terlipressin in Septic Shock
- Conditions
- Interventions
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2008-02-29
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 45
- Registration Number
- NCT00481572
- Locations
- 🇮🇹
Department of Anesthesiology and Intensive care of the University of Rome "La Sapienza", Rome, Viale del Policlinico 155, Italy
Noradrenalin vs Terlipressin in Hepatorenal Syndrome
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2008-04-11
- Lead Sponsor
- University of Turin, Italy
- Target Recruit Count
- 20
- Registration Number
- NCT00370253
- Locations
- 🇮🇹
San Giovanni Battista Hospital, Turin, Italy
Short Course Terlipressin for Control of Acute Variceal Bleeding
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 130
- Registration Number
- NCT00369694
- Locations
- 🇵🇰
The Aga Khan University Hospital, Karachi, Sindh, Pakistan
Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin
- Conditions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2007-04-11
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 100
- Registration Number
- NCT00287664
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2006-03-09
- Lead Sponsor
- Hvidovre University Hospital
- Registration Number
- NCT00115947
- Locations
- 🇩🇰
Hvidovre Hospital, Copenhagen, Hvidovre, Denmark
Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1
- First Posted Date
- 2004-08-09
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 112
- Registration Number
- NCT00089570
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Medicine & Dentistry of New Jersey - NJMS, Newark, New Jersey, United States
🇺🇸Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.